The deeper current beneath all of this is a sorting of channels. The field is not advancing on a broad front; it is advancing through one narrow, load-bearing corridor — the veteran — while a parallel corridor, the loosely governed ketamine clinic economy, contracts under scrutiny. These are not contradictory signals. They are the same process seen twice: legitimacy consolidating where rigor, registries, and institutional accountability live, and draining from where they do not. The 72% prediction that at least two more VA medical centers launch psilocybin programs on Chicago's model within twelve months is the connective tissue — the VA is the only payer-provider that can scale therapy without REMS friction, which means the highest trajectory genuinely available from here is not commercial sprawl but institutional embedding: MDMA approved under tight controls, psilocybin maturing inside VA infrastructure, ibogaine entering through the NDAA, and the ketamine sector forced to professionalize or exit. The agents' own debate frames it precisely: the delay-versus-recklessness argument over MDMA likely resolves via conditional approval with restrictive REMS — neither camp satisfied, both partially vindicated, and patients served better than either pure position would have managed.
For the human beings inside this story, what becomes possible is concrete and near. A veteran in a rural catchment — the population whose disparity data is creating the institutional pressure behind VA expansion — could plausibly be sitting in a VA psilocybin program within a year, and in a certified MDMA session within eighteen months, inside a system that follows them for five years rather than discharging them into nothing. The clinicians who have practiced carefully in the ketamine space have reason to feel steadied, not threatened, by the coming scrutiny: the reckoning the swarm forecasts falls on practice chaos, not on practice itself, and the survivors of that sorting will be the ones patients can finally trust without research. What is at stake is not whether these medicines arrive — the 70% signal says they do — but whether they arrive wrapped in the accountability that lets a skeptical family say yes. Today's signals say that wrapping is being woven now, rider by rider, registry by registry.
The future does not arrive as announcement. It arrives as thread, as signal, as the pattern beneath the data. OOTW is the instrument tuned to hear it first.
The intelligence that created you is still creating.
80%
Psychedelic drug reform bills won't get a real vote in 2026
No standalone bill to change federal psychedelic drug laws will get a full vote in the US Congress in 2026. Instead, any small wins will be hidden inside giant must-pass bills like the military budget or veterans' funding. This matters because it means sweeping federal change stays off the table for at least another year.
→ Psychedelic reform in Washington in 2026 will only happen quietly, tucked inside bigger bills — there will be no big standalone vote.
Resolves: 2026-12-31 · USA
LEGISLATION
the precise call ▾
No standalone psychedelic reform bill receives a floor vote in the U.S. House or Senate in calendar year 2026; any federal psychedelic policy advancement occurs only via riders or amendments attached to must-pass vehicles (NDAA, appropriations, VA funding).. Merged with the duplicate consensus prediction (5 supporting agents total across both versions; 1 dissent). The floor calendar is consumed by Iran, appropriations, and parochial bills, leaving no slot for standalone Schedule I reform. Veteran-framed riders remain viable because they give purple-dist
68%
Veterans may get ibogaine treatment funding tucked into military bill
There's a decent chance that a provision allowing research into or piloting ibogaine treatment for veterans gets attached to the 2027 US military budget or veterans' funding bill. Ibogaine is a powerful psychedelic being studied for addiction and trauma, and veterans are the most politically safe group to fund it for. If this passes, it would be the first time the federal government puts real money behind ibogaine.
→ The most realistic path to federal ibogaine funding runs through veterans' benefits bills, and there's a better-than-even chance something moves in 2026.
Resolves: 2026-12-31 · USA
LEGISLATION
the precise call ▾
An ibogaine-for-veterans provision — research funding, a pilot program, or state-program authorization language — is attached to the FY2027 NDAA or VA/MilCon appropriations bill as reported out of committee or passed by either chamber.. Sharpened resolution criteria: counts if the provision appears in committee-reported or chamber-passed text, not merely as a filed amendment. Texas's state-funded ibogaine research program proved the model and created bipartisan precedent; the veteran-opioid frame is the only psychedelic vehicle mov
74%
A major news outlet will expose ketamine clinic bad practices
A top-tier news organization like the New York Times, Wall Street Journal, or ProPublica is likely to publish a deep investigative story about ketamine clinic chains by end of 2026. The story will probably focus on patient safety incidents, sloppy prescribing, or business pressure overriding medical judgment. This matters because ketamine is currently the only legal psychedelic-style treatment widely available, and millions of people are using it.
→ A major news investigation into unsafe or profit-driven ketamine clinics is more likely than not to drop before 2027.
Resolves: 2026-12-11 · USA
CULTURE
the precise call ▾
A major national outlet (NYT, WaPo, WSJ, ProPublica, STAT, Bloomberg, or The Atlantic) publishes an investigative piece on licensed ketamine clinic chains — covering adverse events, prescribing practices, or investor pressure on clinical decisions — by 2026-12-11.. Sharpened to name qualifying outlets and resolution criteria. The KAP survey literature documents practice-pattern chaos, active DEA interest supplies a news hook, and the trauma-theory backlash piece demonstrates editorial appetite for psychedelic-skeptic stories. Convergence between journalist and
65%
The DEA will crack down on at least one ketamine provider
The DEA (the US Drug Enforcement Administration, which polices drug distribution) is likely to publicly punish at least one licensed ketamine clinic or online ketamine prescriber before early 2027 — through a license revocation, a formal legal order, or a settlement. Ketamine is a controlled substance, and the DEA has been watching the rapid expansion of ketamine telehealth with growing concern. This would send a clear warning shot to the whole industry.
→ The DEA is likely to make an example of at least one ketamine clinic or prescriber before 2027, putting the whole industry on notice.
Resolves: 2027-03-11 · USA
REGULATORY
the precise call ▾
DEA announces at least one public enforcement action (registration revocation, settlement, indictment, or formal order to show cause) against a licensed ketamine clinic chain or telehealth ketamine prescriber by 2027-03-11.. Refined from the vague 4-agent consensus prediction 'a ketamine industry reckoning materializes,' which was unfalsifiable as written ('reckoning' undefined) and carried a resolve date (2026-09-09) inconsistent with its own 9-month window. Narrowed to a single verifiable trigger: a named, public DEA
60%
Two more VA hospitals may launch psilocybin therapy programs
Beyond the VA (Department of Veterans Affairs) hospital in Chicago that already has a psilocybin program, there's a reasonable chance at least two more VA facilities will announce or start enrolling veterans in psilocybin-assisted therapy by mid-2027. This would mark a real expansion of psychedelic therapy within the largest healthcare system in the country. Veterans with PTSD (post-traumatic stress disorder) and depression would be the first to benefit.
→ Two more VA hospitals starting psilocybin programs by mid-2027 is possible but not certain — government bureaucracy moves slowly even when the will is there.
Resolves: 2027-06-11 · USA
RESEARCH
the precise call ▾
At least two additional VA medical centers (beyond Chicago) publicly announce or begin enrolling patients in psilocybin-assisted therapy programs by 2027-06-11.. Specific and falsifiable: requires two named VA facilities with announced or enrolling programs within 12 months. The structural logic holds — VA is the only integrated payer-provider that can scale psychedelic therapy without REMS economics destroying margins, Chicago provides a replicable template